We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche's GS Junior Sequencing System Used in Research on Personalized Tumor Treatment
Product News

Roche's GS Junior Sequencing System Used in Research on Personalized Tumor Treatment

Roche's GS Junior Sequencing System Used in Research on Personalized Tumor Treatment
Product News

Roche's GS Junior Sequencing System Used in Research on Personalized Tumor Treatment


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Roche's GS Junior Sequencing System Used in Research on Personalized Tumor Treatment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This sequencing approach, easily expanded to complete coding regions, has great potential for personalized medicine, where individual treatment success is largely dependent on the mutation status of tumor genes. The high-quality long reads produced by the GS Junior System enable accurate and comprehensive analysis of the full range of genetic variations.

Personalized tumor treatments, such as monoclonal antibodies (mAb) that specifically target tumor-inducing proteins, require a precise and comprehensive assessment of an individual's genetic profile for the targeted genes. Current therapies target only a limited region of the relevant tumor genes, whereas the next-generation GS Junior Sequencing System enables cost effective and comprehensive profiling of all the relevant genes. In contrast, conventional capillary sequencing techniques often lack the sensitivity and cost effectiveness to detect tumor mutations occurring at less than 20% frequency.

"The future of personalized tumor treatment lies in this sequencing approach," said Dr. Hanns-Georg Klein, MD, CEO of both IMGM and the Center for Human Genetics. "Through our research, we've found that it's critical to ensure a comprehensive analysis of a tumor variant population, including known and novel mutations."

These findings underscore the utility of Roche's GS Junior System for investigating complex tumor samples. The long, accurate sequencing reads are ideal for identifying multiple tumor mutations that can include structural variations and rare somatic mutations.

Advertisement